DPI formulation containing sulfoalkyl ether cyclodextrin
View Patent ↗An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
1. A composition, comprising solid particles that comprise sulfoalkylether cyclodextrin, wherein the composition comprises less than 8% by weight moisture, has a bulk density of 0.34 g/cc to 0.55 g/cc, and has a micro-flow fractal dimension analysis of about 1.0-1.2, wherein the composition is prepared by a process comprising a spray agglomeration of a feed solution using a spray drier apparatus to form agglomerated particles.
2. The composition of claim 1 , wherein the composition comprises less than 6% by weight moisture.
3. The composition of claim 1 , wherein the composition comprises a CARR's index of about 10% to about 40%.
4. The composition of claim 1 , wherein the composition comprises particles with a median particle diameter of about 25 microns to about 300 microns.
5. The composition of claim 1 , wherein the composition comprises particles with a median particle diameter of about 175 microns to about 270 microns.
6. The composition of claim 1 , wherein the composition comprises a particle size distribution span of about 1.5 to about 2.9.
7. The composition of claim 1 , wherein the particles are agglomerates.
8. The composition of claim 1 , wherein the particles are aggregates.
9. The composition of claim 1 , wherein the particles are individual particles.
10. The composition of claim 1 , wherein the sufloalkyl ether cyclodextrin is a compound, or a mixture of compounds, of the Formula I:
wherein:
n is 4, 5, or 6;
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each, independently, —O— or a —O—(C 2 -C 6 alkylene)-SO 3 − group, wherein at least one of R 1 to R 9 is independently the —O—(C 2 -C 6 alkylene)-SO 3 − group; and
S 1 , S 2 , S 3 , S 4 , S 5 , S 6 , S 7 , S 8 , and S 9 , are each, independently, a pharmaceutically acceptable cation selected from the group consisting of H + , alkali metals, alkaline earth metals, ammonium ions and amine cations.
11. A pharmaceutical composition comprising the composition of claim 1 and an active agent.
12. A pharmaceutical dosage form comprising the composition of claim 1 .
13. The dosage form of claim 12 , wherein the dosage form is a powder.
14. The composition of claim 1 , wherein the spray drier apparatus comprises a pressure nozzle; an inlet; an outlet; a fluid bed inlet; and a fluid product bed.
15. The composition of claim 14 , wherein the spray agglomeration comprises spraying the feed solution.
16. The composition of claim 14 , wherein the spray agglomeration comprises returning fines at the pressure nozzle.
17. The composition of claim 1 , wherein the composition has a micro-flow fractal dimension analysis of about 1.0-1.1.